This podcast features a panel discussion with pharma and biotech leaders about the past and future direction of pulmonary delivery of biologics. Specifically, the panelists discuss:
- The benefits and costs of different formulation approaches to deliver inhaled therapeutics what needs to be developed to enable more biologics
- Different device approaches including nebulizers, soft mist inhalers, dry powder inhalers and more
- Factors driving new platform and therapeutic development including patient-centricity, legacy technology and time to market
- Next-generation inhaled therapeutics like mRNA vaccines
To learn more about the PODD conference, please visit
Drug-Delivery.org.
